Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inmune Bio ( (INMB) ) has shared an announcement.
On October 23, 2025, INmune Bio Inc. announced it will host a conference call on October 30, 2025, to discuss its third-quarter financial results and provide a corporate update. This event is significant for stakeholders as it will offer insights into the company’s recent performance and strategic direction, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
INmune Bio Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The company has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, the CORDStrom™ platform, and the INKmune® platform, each targeting different diseases and stages of clinical trials.
Average Trading Volume: 1,068,708
Technical Sentiment Signal: Sell
Current Market Cap: $50.51M
See more data about INMB stock on TipRanks’ Stock Analysis page.